GMAB - Genmab A/S
NASDAQ
->
Healthcare
->
Biotechnology
Copenhagen,
Denmark
Type: Equity
GMAB price evolution
GMAB
| (in millions $) | 31 Jan 2024 | 30 Oct 2023 | 30 Jul 2023 | 1 May 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | ||||
| Short term investments | ||||
| Net receivables | $4947 | $5432 | $4814 | $3687 |
| Inventory | $57 | $70 | $51 | |
| Total current assets | $33139 | $33027 | $29749 | $28231 |
| Long term investments | ||||
| Property, plant & equipment | $1641 | $1651 | $1634 | $1596 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $35289 | $35238 | $31978 | $30394 |
| Current liabilities | ||||
| Accounts payable | ||||
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $2484 | $2902 | $1993 | $1955 |
| Long term debt | $680 | $710 | $721 | $740 |
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $3679 | $4126 | $3223 | $3204 |
| Shareholders' equity | ||||
| Retained earnings | $19023 | $18452 | $16165 | $14666 |
| Other shareholder equity | $60 | $142 | $112 | $117 |
| Total shareholder equity | ||||
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 30 Dec 2021 | 30 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $8957 | $7260 | ||
| Short term investments | $10381 | $8819 | ||
| Net receivables | $4947 | $6053 | $3398 | $2712 |
| Inventory | $57 | |||
| Total current assets | $33139 | $28377 | $22736 | $18791 |
| Long term investments | $371 | $1081 | ||
| Property, plant & equipment | $1641 | $1322 | $975 | $736 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $360.33 | |||
| Total investments | ||||
| Total assets | $35289 | $30278 | $24627 | $21143 |
| Current liabilities | ||||
| Accounts payable | $330 | $245 | $350 | $181.54 |
| Deferred revenue | $3.98 | |||
| Short long term debt | ||||
| Total current liabilities | $2484 | $1823 | $1568 | $1253 |
| Long term debt | $680 | $523 | $363 | $277 |
| Total noncurrent liabilities | $117.81 | |||
| Total debt | ||||
| Total liabilities | $3679 | $2837 | $2431 | $2022 |
| Shareholders' equity | ||||
| Retained earnings | $19023 | $14968 | $10020 | $7107 |
| Other shareholder equity | $60 | $98 | $81 | $54 |
| Total shareholder equity | $22196 | $19121 | ||
| (in millions $) | 31 Jan 2024 | 30 Oct 2023 | 30 Jul 2023 | 1 May 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $4678 | $4198 | $2854 | |
| Cost of revenue | ||||
| Gross Profit | $4552 | |||
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $2882 | $2701 | $2417 | |
| Operating income | ||||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | $286 | $366 | $60 | |
| Interest expense | -$744 | $226 | -$151 | |
| Net income | ||||
| Net income | $640 | $1357 | $226 | |
| Income (for common shares) | ||||
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 30 Dec 2021 | 30 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $16474 | $14595 | $8482 | $10111 |
| Cost of revenue | ||||
| Gross Profit | $16248 | $8482 | $10111 | |
| Operating activities | ||||
| Research & development | $4181 | $3115 | ||
| Selling, general & administrative | $1283 | $661 | ||
| Total operating expenses | $10927 | $8238 | $5464 | $3776 |
| Operating income | $3018 | $6335 | ||
| Income from continuing operations | ||||
| EBIT | $3018 | $6335 | ||
| Income tax expense | $1285 | $1513 | $975 | $1146 |
| Interest expense | $316 | $678 | -$13 | -$10 |
| Net income | ||||
| Net income | $4352 | $5522 | $3008 | $4758 |
| Income (for common shares) | $3008 | $4758 | ||
| (in millions $) | 31 Jan 2024 | 30 Oct 2023 | 30 Jul 2023 | 1 May 2023 |
|---|---|---|---|---|
| Net income | ||||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | ||||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | -$1282 | -$840 | -$1848 | -$13 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | -$606 | -$584 | -$604 | -$611 |
| Effect of exchange rate | -$518 | $96 | -$238 | -$216 |
| Change in cash and equivalents | $4974 | $4380 | $981 | $2395 |
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 30 Dec 2021 | 30 Dec 2020 |
|---|---|---|---|---|
| Net income | $3008 | $4758 | ||
| Operating activities | ||||
| Depreciation | $304 | $266 | ||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | $2228 | $6433 | ||
| Investing activities | ||||
| Capital expenditures | -$252 | -$307 | ||
| Investments | -$709 | -$2044 | ||
| Total cash flows from investing | -$1282 | -$2761 | -$961 | -$2351 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | -$58 | -$44 | ||
| Total cash flows from financing | -$606 | -$789 | -$420 | $71 |
| Effect of exchange rate | -$518 | $574 | $850 | -$445 |
| Change in cash and equivalents | $4974 | $936 | $1697 | $3708 |
News
|
Genmab Acquires A Missing Piece For Its Pipeline (NASDAQ:GMAB)
Seeking Alpha
16 Apr 2024
|
|
Genmab reports strong DARZALEX sales in Q1 2024 By Investing.com
Investing.com
16 Apr 2024
|
|
Deal Watch: Kirkland, Simpson, Latham, Cravath Lead $13B Endeavor Buy | The American Lawyer
Law.com
8 Apr 2024
|
|
Medtech Bounds Off 200-Day Line After Crushing Quarterly Views
Investor's Business Daily
4 Apr 2024
|
|
Stocks to Watch Wednesday: Disney, Intel, Tesla, Trump Media
The Wall Street Journal
3 Apr 2024
|
|
Genmab Slumps On Its New $1.8 Billion Deal
Investor's Business Daily
3 Apr 2024
|
|
Genmab Takes The Next Step In Its 'Evolution' With A $1.8 Billion Takeover
Investor's Business Daily
3 Apr 2024
|
|
Denmark stocks lower at close of trade; OMX Copenhagen 20 down 0.67% By Investing.com
Investing.com
1 Apr 2024
|
|
Denmark stocks lower at close of trade; OMX Copenhagen 20 down 0.67% By Investing.com
Investing.com
28 Mar 2024
|
|
Genmab: Growth Is Still a Better Choice
GuruFocus.com via Yahoo Finance
15 Feb 2024
|
Fundamentals
| Market cap | $18.40B |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 646.24M |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | N/A |
| Revenue Q/Q | -10.50% |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | N/A |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 13.34 |
| Quick ratio | 13.32 |